Fiserv missed on the bottom line in a major way in the third quarter, and its stock plunged. It recently got a new CEO who's developing a plan to embed more AI in the business and meet consumer needs.

Vertex Pharmaceuticals' market-beating returns over the past 10 years wouldn't have been enough to turn $100,000 into $1 million. Though it still has strong prospects, this goal seems far too ...

The iPhone recently took the crown to become the world's top-selling smartphone. That's just the tip of the iceberg.

The stock reached $19 per share last October, but today it is 63% below its 52-week high. With shares trading under $9 a ...

So, the best thing an AI investor can do on Feb. 26 is remain calm regardless of which direction the S&P 500 takes. It's important to focus on the long-term AI story, which so far continues to look ...

Even though revenue is under $20 million today, there is a scenario in which AST SpaceMobile generates $1 billion or more in ...

While these deals strengthen Palo Alto's positioning in the cybersecurity space and expand on its platformization strategy, ...

Usually, investors need to see much higher growth to justify this valuation level. Despite Costco's strong digital sales ...

Net stock sales by institutional investors for the week ending Feb. 13 were the second-highest on record. Even though institutional investor skepticism is rising, patience has historically paid off ...

Even with all that, Keytruda's empire, although weakened, should remain strong until the next decade. Merck has received approval for a subcutaneous formulation of the medicine, which has significant ...

Tilray Brands (TLRY 1.65%) bills itself as "a global lifestyle and consumer packaged goods company leading at the nexus of the beverage, cannabis, and wellness industries." While ...